Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LAVA Therapeutics N.V. - Ordinary Shares (NQ:LVTX)

1.610 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LAVA Therapeutics N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts 
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
Analyst Says This Small Cap Stock Might Be 'Game Changer' In Bispecific T Cell Engagers Space
 
Via Benzinga
Why LAVA Therapeutics Stock Is Up More Than 100% Today
LAVA Therapeutics N.V. 
Via Benzinga
LAVA Therapeutics Skyrockets After Cancer Agreement With Seagen
 
Via Benzinga
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022
Upgrades 
Via Benzinga
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
From LAVA Therapeutics N.V.
Via GlobeNewswire
Snap To Surge Around 20%? Here Are 5 Other Price Target Changes For Tuesday
Piper Sandler raised Snap Inc. (NYSE: SNAP) price target from $11 to $12. Piper Sandler analyst Thomas Champion maintained the stock with a Neutral. Snap shares fell 1.4% to close at $10.18 on Monday. 
Via Benzinga
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Nasdaq Turns Lower; Crude Oil Drops Sharply
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite turning negative on Monday. 
Via Benzinga
Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers 
Via Benzinga
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223
LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development 
Via Spotlight Growth
Dow Drops Over 100 Points; Crude Oil Rises Over 1%
U.S. stocks traded mixed midway through trading, with the Dow Jones dropping more than 100 points on Monday. 
Via Benzinga
What Is Going on With Lava Therapeutics (LVTX) Stock Today?
Lava Therapeutics (LVTX) stock is rocketing higher on Monday as investors react to an exclusive global license agreement with Seagen (SGEN). 
Via InvestorPlace
US Stocks Mostly Higher; Nasdaq Rises Over 100 Points
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday. 
Via Benzinga
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
From Seagen Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
Upgrades 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share. 
Via Benzinga
LAVA Therapeutics Shares Interim LAVA-051 Data From Early-Stage Cancer Trial
LAVA Therapeutics NV (NASDAQ: LVTX) announced initial data from its first clinical study with LAVA-051. The presentation will include data from the first... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares climbed 52.8% to close at $5.56 on Monday. Collegium Pharmaceutical will acquire BioDelivery Sciences... 
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
40 Biggest Movers From Friday
Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean Intellectual Property Office has fully issued its... 
Via Benzinga
The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of Moderna's COVID-19 Vaccine Booster Shot For... 
Via Benzinga
35 Biggest Movers From Friday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.